ArticleJournal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases2026
Preinfusion Glucocorticoid Reduction and Elimination in Patients With Uncontrolled Gout on Pegloticase and Methotrexate: A Case Series.
Article in Journal of clinical rheumatology : practical reports on rheumatic & musculoskeletal diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
objectivePegloticase, an infused pegylated uricase enzyme, rapidly lowers serum urate (SU) in patients with uncontrolled gout. Preinfusion intravenous glucocorticoids (GCs) are typically administered before pegloticase to reduce risks of infusion reactions (IRs); however, they may exacerbate comorbidities in this patient population, and thus minimizing GC exposure is desirable. This study examined preinfusion GC dose reduction and elimination in patients with uncontrolled gout receiving pegloticase and methotrexate (MTX) co-therapy.
methodsThis retrospective case series of medical data (January 1, 2020, to April 1, 2023) from 1 rheumatology practice included patients receiving pegloticase (8 mg every 2 wk) with MTX co-therapy and undergoing preinfusion methylprednisolone dose reduction and elimination. The percentage of patients with SU <6 mg/dL (pegloticase responders) was assessed at 6 months and study completion; safety was assessed by frequency and severity of adverse events.
resultsTwelve patients with multiple comorbidities were evaluated (male, 92%; White, 58%; mean [SD] age, 60.3 [11.0] years; mean [SD] baseline SU, 8.8 [1.9] mg/dL). Patients received a mean (SD) of 14.3 (4.2) pegloticase infusions and discontinued GCs after a mean (SD) of 7.6 (1.3) infusions. At 24 weeks, 10/12 (83%) patients were responders and 9/12 (75%) continued to respond following GC reduction and elimination; 3/12 (25%) had an SU rise and discontinued pegloticase. The most common adverse event was gout flare (10/12 [83%] patients); no patients experienced IRs.
conclusionsThis study demonstrated that preinfusion GC reduction and elimination are possible in patients with uncontrolled gout receiving pegloticase and MTX co-therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.